Patient Advocates Call For Science-Led Transition on Animal Research Alternatives
As federal agencies accelerate efforts to expand the use of non-animal research methods, a growing coalition of patient advocacy organizations is urging policymakers to ensure that scientific evidence - not ideology - drives the transition. Their message is clear: innovative technologies such as organoids, organ-on-chip systems, artificial intelligence, and advanced computational modeling hold enormous promise, but they are not yet capable of replacing animal models across all areas of biomedical research. The goal should be to replace, reduce, and refine animal use where scientifically validated - not to eliminate animal research before suitable alternatives exist. The NIH's recently established Office of Research Innovation, Validation, and Application (ORIVA) reflects that balanced approach by focusing on developing and validating human-based research methods while recognizing that animal studies remain necessary in many areas today.
That distinction has become increasingly important as patient organizations representing individuals with Alzheimer's disease, Parkinson's disease, ALS, muscular dystrophy, cystic fibrosis, cancer, rare genetic disorders, and other serious conditions voice concern that premature restrictions on animal research could delay the discovery of desperately needed therapies. As highlighted in a recent Drug Discovery News feature, complex biological processes—including immune responses, neurological diseases, developmental biology, and whole-body drug metabolism—still cannot be fully replicated using current laboratory models alone.
The NIH similarly acknowledges that while New Approach Methodologies (NAMs) continue to advance rapidly, they cannot yet fully replace animal models across the spectrum of biomedical research. Animal studies remain an essential component of understanding disease mechanisms, evaluating safety, and generating the evidence required before new therapies can advance into human clinical trials.
The issue has particular relevance in Michigan, where some elected officials have introduced legislation that would prohibit or significantly restrict certain categories of animal research at public institutions. One example is HB 4254, which would prohibit research or training involving dogs whenever procedures could cause pain or distress, despite the fact that such studies are already subject to extensive federal oversight, ethical review, veterinary supervision, pain-management requirements, and Institutional Animal Care and Use Committee (IACUC) approval.
Supporters of these measures are motivated by legitimate concerns for animal welfare. However, many in Michigan's research community - including universities, medical centers, bioscience companies, and patient advocacy organizations - warn that legislation restricting scientifically justified animal research without validated alternatives could have unintended consequences. Research programs may relocate to other states or countries, federal grant funding could decline, collaborations could be disrupted, and promising therapies for patients could be delayed. These concerns extend beyond research institutions themselves, affecting startup formation, venture investment, high-skilled employment, and Michigan's broader life sciences economy.
Michigan has built one of the nation's strongest life sciences ecosystems, anchored by the University of Michigan, Michigan State University, Wayne State University, Corewell Health, Henry Ford Health, and an expanding network of biotechnology, pharmaceutical, medical device, and diagnostics companies. Together, these organizations secure more than $1 billion annually in NIH funding and conduct research spanning cancer, neuroscience, cardiovascular disease, regenerative medicine, infectious diseases, rare disorders, and advanced medical technologies.
At the same time, Michigan is helping develop many of the very alternatives that researchers hope will eventually reduce reliance on animal models, including AI-enabled drug discovery, organoid technologies, computational biology, advanced imaging, and precision medicine platforms. Rather than viewing these technologies as replacements today, many scientists see them as complementary tools that can improve research efficiency while reducing animal use wherever scientifically appropriate.
For MichBio and its members, the path forward is not an either-or proposition. Continued investment in validated alternative methods should be encouraged and accelerated. But policies governing biomedical research must remain grounded in scientific evidence and patient need. Until replacement technologies are fully validated across the breadth of human disease, carefully regulated animal research will continue to play an indispensable role in developing the next generation of medicines, diagnostics, vaccines, and medical devices. Striking that balance will be essential if Michigan is to remain a leader in biomedical innovation while advancing both scientific excellence and humane research practices.
